Migraine Snapshot: Despite Significant Generic Presence, MAP, Allergan, Others See Big Market Potential

After a 20-year hiatus, the market for acute and chronic migraine is set to expand with the introduction of Allergan’s Botox and of novel formulations of triptans and alternative therapies.